This article is more than 5 years old. Information may no longer be current.
Motesanib plus carboplatin, paclitaxel extended survival in NSCLC
The addition of motesanib to carboplatin and paclitaxel improved OS, PFS and response rates in patients with nonsquamous non–small cell lung cancer, according to results of a phase 3 study.
The subset analysis of the MONET1 trial included 227 Asian patients with stage IIIb/IV or recurrent disease who had not received prior systemic therapy for advanced NSCLC.
All patients received up to six 3-week cycles of IV carboplatin (area under the curve, 6 mg/ml minimum) and 200 mg/m2 paclitaxel. Patients also received either placebo or 125 mg daily motesanib (AMG 706, Takeda), an oral small-molecule antagonist of vascular endothelial growth factor, platelet-derived growth factor and stem cell factor receptors.
OS served as the study’s primary endpoint. PFS, overall response rate and safety served as secondary endpoints.
Patients assigned motesanib demonstrated improved median OS (20.9 months vs. 14.5 months; P=.0223) and PFS (7 months vs. 5.3 months; P=.0004) compared with those assigned placebo. Researchers also reported a significantly higher overall response rate in the motesanib arm (62% vs. 27%; P˂.0001).
More patients assigned motesanib experienced grade ≥3 adverse events (79% vs. 61%).
Disclosure: See the study for a full list of the researchers’ relevant financial disclosures.